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Abstract
Objective: Platelet count has been proposed as a screening test 
for generalized coagulopathy in women with preeclampsia We 
performed this study to determine the relationship between 
platelet counts and the risk of abnormal coagulation and adverse 
maternal outcomes in women with preeclampsia
Methods: We used data from women in the PIERS (Pre-eclampsia 
Integrated Estimate of RiSk) database Abnormal coagulation 
was de¿ned as either an international normalized ratio result 
greater than and/or a serum ¿brinogen level less than the BC 
Women’s Hospital laboratory’s pregnancy-speci¿c normal range
The relationship between platelet counts and adverse maternal 
outcomes was explored using a logistic regression analysis The 
sensitivity, speci¿city, positive predictive value, and negative 
predictive value of platelet counts in identifying abnormal 
coagulation or adverse maternal outcomes were calculated
Reslts: Abnormal coagulation occurred in 105 of 1405 eligible 
women (75%) The odds of having abnormal coagulation were 
increased for women with platelet counts < 50 × 109/L (OR 778; 
95% CI 336 to 1803) and between 50 and 99 × 109/L (OR 269; 
95% CI 144 to 501) compared with women who had platelet 
counts above 150 × 109/L Platelet counts < 100 × 109/L were 
associated with signi¿cantly increased odds of adverse maternal 
outcomes, most speci¿cally blood transfusion A platelet count 
of < 100 × 109/L had good speci¿city in identifying abnormal 
coagulation and adverse maternal outcomes (92% [95% CI  
91% to 94%] and 92% [95% CI 91% to 94%], respectively), but 
poor sensitivity (22% [95% CI 15% to 31%] and 16% [95% CI 
11% to 23%], respectively)
Conclsion: A platelet count < 100 × 109/L is associated with an 
increased risk of abnormal coagulation and maternal adverse 
outcomes in women with preeclampsia However, the platelet 
count should not be used in isolation to guide care because of its 
poor sensitivity Whether or not a platelet count is normal should 
not be used to determine whether further coagulation tests are 
needed
Résmé
Objectif : Le recours à la numération plaquettaire a été proposé à 
titre de test de dépistage visant la coagulopathie généralisée 
chez les femmes qui présentent une prééclampsie Nous 
avons mené cette étude pour déterminer la relation entre les 
numérations plaquettaires et le risque de coagulation anormale 
et d’issues maternelles indésirables chez les femmes qui 
présentent une prééclampsie
Méthodes : Nous avons utilisé des données issues de participantes 
à la base de données PIERS (Pre-eclampsia Integrated 
Estimate of RiSk) La coagulation anormale a été dé¿nie comme 
étant un résultat de rapport international normalisé se situant 
au-delà de la plage normale propre à la grossesse du laboratoire 
du BC Women’s Hospital et/ou comme étant un taux sérique 
de ¿brinogène se situant en deçà de cette plage La relation 
entre les numérations plaquettaires et les issues maternelles 
indésirables a été explorée au moyen d’une analyse de 
régression logistique La sensibilité, la spéci¿cité, le coef¿cient 
de prévision d’un test positif et le coef¿cient de prévision d’un 
test négatif propres aux numérations plaquettaires pour ce qui 
est de l’identi¿cation d’une coagulation anormale ou d’issues 
maternelles indésirables ont été calculés
Résltats : Une coagulation anormale s’est manifestée chez 105 des 
1 405 femmes admissibles (7,5 %) Les risques de présenter 
une coagulation anormale étaient accrus chez les femmes qui 
comptaient des numérations plaquettaires < 50 × 109/l 
(RC, 7,78; IC à 95 %, 3,36 - 18,03) et se situant entre 50 et  
99 × 109/l (RC, 2,69; IC à 95 %, 1,44 - 5,01), par comparaison 
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avec les femmes qui comptaient des numérations plaquettaires 
se situant au-delà de 150 × 109/l Les numérations plaquettaires 
< 100 × 109/l ont été associées à une hausse signi¿cative des 
risques de connaître des issues maternelles indésirables, plus 
particulièrement une transfusion sanguine Une numération 
plaquettaire < 100 × 109/l présentait une bonne spéci¿cité pour 
ce qui est de l’identi¿cation d’une coagulation anormale et 
d’issues maternelles indésirables (92 % [IC à 95 %, 91% - 94%] 
et 92 % [IC à 95 %, 91 % - 94 %], respectivement), mais une 
faible sensibilité (22 % [IC à 95 %, 15 % - 31 %] et 16 % [IC à 
95 %, 11 % - 23 %], respectivement)
Conclsion : Une numération plaquettaire < 100 × 109/l est associée à 
un risque accru de  coagulation anormale et d’issues maternelles 
indésirables chez les femmes qui présentent une prééclampsie
Toutefois, la numération plaquettaire ne devrait pas être utilisée 
de façon isolée pour orienter les soins, et ce, en raison de sa 
faible sensibilité Le caractère normal ou non d’une numération 
plaquettaire ne devrait pas être utilisé pour déterminer si la tenue 
d’autres tests de coagulation s’avère requise
INTRODuCTION
Preeclampsia is a complex, multi-system disorder that remains a signiÀcant cause of  maternal morbidity 
and mortality worldwide.1 Preeclampsia seems to result 
from a mismatch between fetoplacental demands and 
the ability of  the maternal uterine blood supply to meet 
those demands, which leads to the release of  vasoactive 
and innate immune activating substances in the maternal 
circulation, with subsequent endothelial and innate immune 
activation.2,3 This leads to maternal clinical manifestations, 
which include hypertension, renal and hepatic dysfunction, 
systemic inÁammation, and hematological abnormalities. 
These hematological abnormalities usually manifest as 
mild and indolent consumptive coagulopathies, including 
consumption of  platelets, clotting factors, and Àbrinogen. 
Occasionally, these abnormalities become severe, for 
example manifesting as disseminated intravascular 
coagulation, which can be life-threatening.3,4
The care of  women with preeclampsia should be based 
on the goal of  reducing maternal and perinatal risks, 
two priorities that may be in conÁict remote from term. 
Several studies have supported the use of  a platelet count 
threshold (100 × 109/L) above which even women with 
severe preeclampsia are unlikely to have abnormalities 
in aPTT, INR, or serum Àbrinogen.5–7 This threshold 
has been endorsed by the Society of  Obstetricians and 
Gynaecologists of  Canada in the absence of  placental 
abruption.8 Standardized assessment and surveillance 
guidelines in British Columbia include the aforementioned 
laboratory assessments of  coagulation, but recommend 
that aPTT, INR, and serum Àbrinogen be measured in 
every woman with suspected or conÀrmed preeclampsia; 
this regimen of  investigation is associated with reduced 
maternal risk.9,10 Coagulation tests, which are expensive, are 
generally used to identify bleeding risk prior to Caesarean 
section or vaginal birth in order to avoid maternal 
hemorrhage, as well as to identify the risk of  epidural 
hematoma in women requesting neuraxial blockade.11
The purpose of  this study was to determine the relationship 
between platelet count and the risk of  an abnormal 
coagulation test (INR or serum Àbrinogen) in women 
with preeclampsia. A secondary aim was to establish the 
relationship between platelet count or the occurrence of  
one or more abnormal coagulation test results with blood 
transfusion and/or other elements of  a combined adverse 
maternal outcome within 48 hours of  hospital admission.
METHODS
The data used for this study were extracted from PIERS 
database. PIERS is a prospective study of  women with 
preeclampsia admitted to tertiary obstetric centres in 
which there is a general policy of  expectant management 
of  preeclampsia remote from term. Full details of  the 
PIERS methodology have been published elsewhere.12
Data were collected on women admitted from September 
2003 to January 2010 to eight tertiary perinatal centres: 
four in Canada, two in the United Kingdom, one in 
New Zealand, and one in Australia. In four sites, until 
September 2007, women were required to give informed 
consent for enrolment in PIERS. In three of  those four 
sites (after September 2007), and in all other sites since 
joining the study, PIERS was conducted as a continuous 
quality improvement project. The continuous quality 
improvement project entailed the introduction of  
predetermined guidelines for the initial assessment and 
ongoing surveillance of  women admitted to hospital with 
suspected or conÀrmed preeclampsia. The details of  these 
guidelines have been published elsewhere.9,10
Women were included in the PIERS study if  they met 
any one of  the following inclusion criteria: (1) BP ≥ 
140/90 mmHg (on at least two occasions ≥ 4 hours apart 
after 20 weeks’ gestation, by any method in the hospital) 
ABBREVIATIONS
aPTT activated partial thromboplastin time
BP blood pressure
dBP diastolic blood pressure
HELLP hemolysis, elevated liver enzymes, and low platelet
INR international normalized ratio
PIERS Pre-eclampsia Integrated Estimate of RiSk
sBP systolic blood pressure
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and either proteinuria (of  ≥ 2+ by dipstick, ≥ 0.3 g/d 
by 24-hour urine collection, or > 30 mg/mmol by spot 
urinary protein:creatinine ratio) or hyperuricemia (greater 
than local upper limit of  normal for non-pregnant 
individuals); (2) HELLP syndrome even in the absence 
of  hypertension or proteinuria; or (3) superimposed 
preeclampsia, deÀned as pre-existing hypertension with 
accelerated hypertension (as diagnosed by the clinician, 
or deÀned as a sBP ≥ 170 mmHg or dBP ≥ 120 mmHg), 
new proteinuria, or new hyperuricemia. Women were 
excluded if  they were admitted in active labour or if  they 
achieved any component of  the maternal outcome prior 
to collection of  predictors. This inclusive deÀnition was 
chosen to reÁect the variable and multisystem nature of  
preeclampsia seen in clinical practice.13–15
The list of  adverse maternal outcomes recorded by 
PIERS was developed by iterative Delphi consensus16,17
and includes maternal mortality and any of  the following 
maternal morbidities: hepatic dysfunction, hematoma, or 
rupture; eclampsia; Glasgow Coma Scale score < 13; stroke; 
reversible ischemic neurological deÀcit; transient ischemic 
Table 1. Characteristics of women in the PIERS stdy  (N = 1405)
Characteristic
Abnormal coagulation*
(n = 105 women)
Normal coagulation
(n = 1300 women) P**
Demographics (within 48h of eligibility)
Maternal age at EDD (years), median (interquartile range) 30 (26 to 34) 32 (28 to 36) 0004
Gestational age at eligibility (weeks), median (interquartile range) 327 (303 to 367) 364 (334 to 384) <0001
Gestational age at eligibility < 34 weeks, n (%) 59 (562) 362 (278) <0001
Multiple pregnancy, n (%) 10 (95) 142 (109) 0657
Parity ≥ 1, n (%) 30 (286) 354 (272) 0767
Smoking in this pregnancy, n (%) 15 (143) 138 (106) 0336
Preeclampsia description 
Hypertension and proteinuria, n (%) 76 (724) 841 (647) 0321
Hypertension and hyperuricaemia, n (%) 11 (105) 212 (163)
HELLP without hypertension or proteinuria, n (%) 7 (67) 39 (30)
Superimposed preeclampsia, n (%) 11 (105) 208 (160)
Clinical (within 48h of eligibility)
Peak blood pressure (mmHg)
Mean arterial pressure, median (interquartile range) 1213 (1152 to 1300) 1213 (1150 to 1300) 0799
sBP, median (interquartile range) 161 (150 to 180) 162 (151 to 178) 0534
dBP 103 (100 to 110) 102 (98 to 110) 0740
Worst dipstick proteinuria, median (interquartile range) 2 (1 to 3) 2 (1 to 3) 0911
Highest aspartate transaminase, median (interquartile range) 375 (22 to 845) 29 (22 to 42) 0002
Interventions
Corticosteroid administration, n (%) 46 (438) 348 (268) <0001
Antihypertensive medications administered, n (%) 78 (743) 880 (677) 0163
MgSO4 administered, n (%) 55 (524) 437 (336) <0001
Pregnancy outcomes
Admission-to-delivery interval (all cases) (d), median (interquartile range) 2 (1, 6) 2 (1, 5) 0611
Gestational age at delivery (wk), median (interquartile range) 336 (306 to 369) 370 (345 to 387) <0001
Placental abruption, n (%) 3 (29) 26 (20) 0473
Birth weight (g), median (interquartile range) 2387 (1270 to 3110) 2635 (1822 to 3270) 0006
Birth weight  < 3rd percentile (n babies) (41), n (%) 9 (86) 109 (84) 0949
Intrauterine fetal death (≥ 20+0 wk and/or ≥ 500g), n (%) 1 (09) 12 (09) 0976
Neonatal death (before 28d), n (%) 2 (19) 14 (11) 0442
Infant death prior to hospital discharge or 6wk, n (%) 2 (19) 17 (13) 0611
**Elevated INR, and/or decreased ¿brinogen, compared with normal third trimester range
**P calculated using Mann-Whitney U for continuous variables and Fisher exact test for categorical except preeclampsia description, which used chi-squared test
EDD: expected date of delivery
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attack; posterior reversible encephalopathy; cortical 
blindness or retinal detachment; need for positive inotrope 
support; infusion of  a third parenteral antihypertensive; 
myocardial ischemia or infarction; acute renal insufÀciency 
(in women without prior renal disease)18; acute renal failure 
(in women with prior renal disease)18; dialysis; pulmonary 
edema; oxygen saturation by pulse oximetry < 90%; 
requirement of  ≥ 50% FiO2 for > 1 hour; intubation (other than solely for Caesarean section); placental abruption; and 
transfusion of  any blood product.
The lowest platelet count within 48 hours of  eligibility was 
used for analysis. For women with an adverse outcome, 
the lowest value prior to the occurrence of  an adverse 
outcome was used. Abnormal coagulation was deÀned 
as an INR result greater than and/or a serum Àbrinogen 
level less than the third trimester pregnancy ranges at 
the BC Women’s Hospital and Health Centre in British 
Columbia. These threshold levels are INR > 1.06 and 
serum Àbrinogen < 3.54 g/L. Only women with a platelet 
count and recorded values for INR and Àbrinogen within 
12 hours of  their relevant platelet count were included 
in the study. We excluded aPTT from the deÀnition of  
this outcome because of  the high proportion of  patients 
in whom the test was never performed and also because 
of  the possibility that aPTT could be prolonged by the 
presence of  antiphospholipid antibodies or high doses of  
heparin given for thromboprophylaxis.
The demographics of  women with or without abnormal 
coagulation were compared using a Mann-Whitney 
U test for continuous variables and a Fisher exact test for 
categorical variables, except in the case of  the description 
of  preeclampsia, for which a chi-squared test was used. To 
explore the possibility of  a non-linear relationship between 
platelet count and abnormal coagulation, platelet count was 
modeled as a restricted cubic spline with 5 knots. This allowed 
a smooth, curvilinear relationship to be generated, which was 
used to identify logical threshold values for further analysis. 
Threshold values of  100 × 109/L and 50 × 109/L were also 
analyzed to be consistent with current clinical practice. The 
occurrence of  each abnormal coagulation test result, any 
adverse maternal outcome within 48 hours of  eligibility for 
the study, and the need for blood transfusion were assessed 
using logistic regression. The regression models generated 
for this study were univariable, and included only platelets or 
abnormal coagulation as individual predictors. For platelets, 
the variables were entered into the regression model as 
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multiple dummy variables, one for each platelet range, with the 
highest range (> 150 × 109/L) used as the reference group. 
Abnormal coagulation was assessed as a categorical variable 
that was based on the patient either meeting or not meeting 
our research deÀnition for abnormal coagulation. We assessed 
the diagnostic value of  different platelet count thresholds by 
calculating sensitivity, speciÀcity, positive predictive value, and 
negative predictive value. Statistical analyses were performed 
using STATA version 10.0 or SPSS version 18.0 (IBM Corp., 
Somers NY)
Research Ethics Board approval was obtained at all sites.
RESuLTS
Of  the 2023 women in the PIERS cohort, 1405 (69.5%) 
were eligible for this study. Of  the 1405 included here, a total 
of  122 (8.7%) women had a platelet count < 100 × 109/L, 
and 105 women (7.5%) had abnormal coagulation as 
deÀned by an abnormal INR, serum Àbrinogen, or both, 
on the same blood sample as the worst platelet count. 
Of  those 105 women, 23 (21.9%) had a platelet count 
< 100 × 109/L. In total, 152 (10.8%) women had one or 
more adverse maternal outcomes during their hospital 
stay. The most common adverse outcomes were a need for 
blood transfusion, which occrred in 60 women (4.3%) and 
pulmonary edema, which occurred in 35 women (2.5%). A 
full list of  the PIERS adverse maternal outcomes and rates 
within the cohort can be found elsewhere.19
The baseline characteristics of  the women included in the 
study with and without abnormal coagulation test results 
are shown in Table 1. Women with abnormal coagulation 
test results were younger, had earlier onset of  disease (as 
seen by the lower gestational age at onset and delivery), 
had higher aspartate transaminase levels, and were more 
often given corticosteroids and magnesium sulphate. 
There was no difference between groups in the rate of  
placental abruption.
The relationship between platelet count and the 
probability of  abnormal coagulation, as assessed using 
a logistic regression model with platelet count Àtted as 
a restricted cubic spline, is shown in Figure. Using this 
Àgure, the additional threshold level of  a platelet count of  
150 × 109/L was identiÀed for further analysis.
The rates of  abnormal coagulation and adverse maternal 
outcomes corresponding to various platelet count ranges and 
the odds of  outcome occurrence in each of  these groups 
compared with the reference group (> 150 × 109/L) are 
shown in Table 2. The odds of  abnormal coagulation were 
signiÀcantly increased among women with a platelet count of  
< 50 × 109/L (OR 7.79; 95% CI 3.36 to 18.04) and between 
50 and 99 × 109/L (OR 2.69; 95% CI 1.44 to 5.02) compared 
with women whose platelet count was ≥ 150 × 109/L. Odds 
of  any adverse maternal outcome, and speciÀcally the need 
for blood transfusion, were also increased with a platelet 
count ≤ 50 × 109/L or between 50 and 99 × 109/L.
The odds ratios for any adverse maternal outcome or 
blood transfusion alone were 2.55 (95% CI 1.55 to 4.19) 
and 3.77 (95% CI 1.97 to 7.21), respectively in women with 
Table 2.  Platelet cont among women with preeclampsia and odds of abnormal coaglation 
or adverse maternal otcome (n = 1405)
Platelet count (×109/L)
< 50 50 to 99 100 to 149 ≥ 150
Outcome 27 95 273 1010
Abnormal coagulation* 
n (%) 9 (333) 14 (147) 21 (77) 61 (60)
OR (95% CI) 778†
(336 to 1804)
269†
(144 to 502)
130
(078 to 217)
reference
Adverse maternal outcome
n (%) 15 (555) 9 (95) 26 (95) 102 (101)
OR (95% CI) 1132†
(519 to 2468)
221†
(136 to 358)
129
(090 to 185)
reference
Blood transfusion 
n (%) 12 (444) 7 (74) 10 (37) 31 (31)
OR (95% CI) 2527†
(1092 to 5847)
251†
(108 to 587)
120
(058 to 248)
reference
*Elevated INR, and/or decreased ¿brinogen, compared with normal third trimester range
†Marked results found to be signi¿cant (P < 005)
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one or more than one abnormal coagulation test results 
compared with those with normal coagulation test results.
We performed a sensitivity analysis examining only non-
hematological outcomes, and found a signiÀcant association 
between a platelet count < 50 × 109/L and the outcome 
(OR 5.68; 95% CI 1.85 to 17.45). A sensitivity analysis was 
also performed, grouping cases by diagnosis at enrolment 
(hypertension and proteinuria or HELLP, hypertension and 
hyperuricaemia, and superimposed preeclampsia), and a similar 
association with all outcomes was found (data not shown).
The efÀciency of  using platelet count thresholds of  
100 × 109/L and 150 × 109/L to identify women with 
abnormal coagulation, the PIERS combined adverse 
maternal outcome, or the need for blood transfusion 
speciÀcally is shown in Table 3, presenting the sensitivity, 
speciÀcity, positive predictive value, and negative predictive 
value. The ability of  abnormal coagulation test results to 
predict the PIERS combined adverse maternal outcome or 
blood transfusion alone is also shown in Table 3. All tests 
showed negative predictive value and speciÀcity > 90%, 
but low sensitivity and positive predictive value.
DISCuSSION
Within our cohort of  1405 women with preeclampsia 
admitted to tertiary perinatal units, thrombocytopenia, 
deÀned by a platelet count < 150 × 109/L, occurred in 395 
women (28.1%). Abnormal coagulation test results were 
unusual in the study cohort, occurring in only 105 women 
(7.5%). This is consistent with previous studies and 
reports.5–7,20–23 In addition, platelet counts < 100 × 109/L 
were found to be associated with abnormal coagulation 
test results. As clinicians would expect, both low platelet 
counts and abnormal coagulation were associated with an 
increased risk of  adverse maternal outcome(s) or blood 
transfusion speciÀcally.
Our Ànding that a platelet count < 100 × 109/L was 
not a sensitive indicator of  abnormal coagulation was 
surprising. Even if  a platelet count < 150 × 109/L was 
used as the threshold for a positive test, only 42% of  
women with abnormal coagulation would have been 
correctly identiÀed. It is important to note that of  the 1283 
women with a platelet count > 100 × 109/L (91.3% of  the 
study cohort), 82 (6.4%) had the outcome of  abnormal 
coagulation. Although this is signiÀcantly less than the rate 
of  abnormal coagulation found in women with platelet 
counts < 100 × 109/L in this population (18.9%), it 
may be clinically signiÀcant, given the association found 
between abnormal coagulation and the adverse maternal 
outcomes. These results do not fully support the Àndings 
of  Leduc et al.7 who studied 100 women with severe 
preeclampsia and concluded that abnormal coagulation 
(deÀned by low serum Àbrinogen or elevated aPTT) was 
always associated with thrombocytopenia. Other similar 
Table 3. utility of platelet conts in identifying abnormal coaglation or adverse maternal otcomes in women  
with preeclampsia
Outcome Test
Sensitivity, %  
(range) 
Speci¿city, %  
(range)
PPV, %  
(range)
NPV, %  
(range)
Abnormal coagulation* Platelet < 100 × 109/L 219
(146 to 312)
924
(908 to 937)
188
(126 to 272)
936
(921 to 949)
Platelet < 150 × 109/L 419
(325 to 519)
730
(705 to 754)
111
(83 to 148)
940
(923 to 953)
Adverse maternal outcome† Platelet < 100 × 109/L 158
(106 to 228)
922
(905 to 936)
197
(132 to 281)
900
(882 to 916)
Platelet < 150 × 109/L 329
(256 to 410)
725
(699 to 749)
127
(96 to 164)
899
(878 to 917)
Blood transfusion Platelet < 100 × 109/L 317
(206 to 451)
923
(908 to 937)
156
(99 to 235)
968
(956 to 977)
Platelet < 150 × 109/L 483
(354 to 615)
728
(703 to 751)
73
(51 to 105)
969
(956 to 979)
Adverse maternal outcome† Abnormal coagulation* 151
(100 to 221)
935
(919 to 947)
219
(147 to 312)
901
(883 to 916)
Blood transfusion Abnormal coagulation* 217
(125 to 345)
932
(916 to 944)
124
(70 to 206)
964
(952 to 973)
NPV: negative predictive value; PPV: positive predictive value
*Elevated INR and/or decreased ¿brinogen, compared with normal third trimester range
†See text for details
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studies resulted in the same conclusion for women with 
severe preeclampsia.5,6,22 The differences in our results are 
likely due to our larger sample size and may also have been 
affected by the inclusion in our cohort of  women with 
mild as well as severe disease.
DeÀning adequate sensitivity and speciÀcity for a 
screening test to be used in clinical practice requires 
that we consider the implications of  false-positive or 
false negative results.24,25 In clinical practice, the platelet 
count is recommended as a screening test in women with 
hypertension in pregnancy to determine if  further tests of  
coagulation are required. With a high false-negative rate, 
and consequently low sensitivity, platelet count screening 
would result in women with abnormal coagulation not 
being identiÀed before interventions such as Caesarean 
section or neuraxial anaesthesia. When clinicians are aware 
of  coagulation abnormalities, they will adjust practice to, 
for example, place an abdominal drain after a Caesarean 
section or withhold neuraxial anaesthesia. Although we 
did not have any complications of  epidural anaesthesia in 
our cohort, this is likely because all women had tests of  
coagulation, beyond the platelet count, performed as part 
of  their routine surveillance.
A high false-positive rate, in this case, would mean more 
women would undergo further coagulation tests (Àbrinogen, 
aPTT, INR) than necessary, but this would not necessarily 
affect clinical practice adversely. Having high sensitivity is 
critical, more so than having high speciÀcity. In our study, 
neither a cut-off  platelet count of  < 100 × 109/L nor one of  
< 150 × 109/L had great sensitivity for predicting abnormal 
coagulation. Even if  the upper limit of  conÀdence intervals 
around the point estimates of  sensitivity was correct, 
we would still identify only 30% to 50% of  women with 
abnormal coagulation. Given the consequences of  a missed 
positive test, this yield is not adequate.
The situation is similar when considering the use of  the 
platelet count as an independent predictor of  adverse 
maternal outcomes. Failing to identify women who are at 
great risk of  an adverse outcome could result in signiÀcant 
morbidity and possibly even mortality. This is particularly 
relevant when managing women in rural and remote settings. 
On the other hand, over-identifying women at risk may lead 
to unnecessary interventions and, in the case of  early onset 
disease, iatrogenic prematurity and increased risk to the 
fetus. In this case, both a high sensitivity and high speciÀcity 
would be required to make a treatment decision.
Using a cut-off  platelet count of  < 100 × 109/L resulted 
in high speciÀcity when predicting adverse maternal 
outcomes or blood transfusion alone, but low sensitivity 
(16% for any adverse maternal outcome and 32% for blood 
transfusion alone). The high negative predictive value and 
speciÀcity are likely due to the low incidence of  adverse 
outcomes in the population and are not truly reÁective of  
the efÀcacy of  the test. Similar results were found when 
abnormal coagulation was used as a predictor of  adverse 
maternal outcomes.
When the efÀcacy of  abnormal coagulation as a predictor 
of  adverse maternal outcomes was compared with platelet 
count based on sensitivity, speciÀcity, negative predictive 
value and positive predictive value, we found no difference. 
This implies that measuring INR or serum Àbrinogen does 
not add any clinical advantage to testing for platelet count 
alone in these cases. This argument is further strengthened 
by the results of  the fullPIERS model. When coagulation 
tests and platelet count were evaluated among several 
other candidate predictor variables for inclusion in the 
fullPIERS model, platelet count remained in the model, 
while coagulation tests did not.26 The Ànal variables in 
the fullPIERS model were gestational age at onset of  
preeclampsia, occurrence of  chest pain or dyspnea, oxygen 
saturation by pulse oximetry, serum creatinine level, platelet 
count, and aspartate transaminase level.26
A limitation of  this study is that we did not collect 
data on the presence of  either inherited or acquired 
thrombophilias in past medical history. This was because 
in our interim analysis of  the Àrst 1250 women in the total 
PIERS cohort we did not Ànd any relationship between 
history of  thrombophilia and adverse maternal outcome in 
women who were admitted with preeclampsia. This does 
not address the issue of  whether or not thrombophilias 
and preeclampsia coaggregate,3 but it does suggest that 
thrombophilias do not add incrementally to the maternal 
risks of  preeclampsia after the diagnosis has been made.
In addition, aPTT results and information on 
antiphospholipid antibodies were excluded from the 
deÀnition of  abnormal coagulation in this study because 
they were not uniformly performed on women in the 
PIERS cohort. Antiphospholipid antibodies have been 
reported as prevalent (10% to 30%) among women with 
preeclampsia.27,28 Excluding aPTT from our deÀnition 
of  the outcome “abnormal coagulation” was felt to be 
appropriate because clinicians clearly did not feel it was an 
important investigation.
A second limitation of  the study is that it had only 
sufÀcient statistical power to investigate the relationship 
between platelet count at a single time point and abnormal 
coagulation test results or need for blood transfusion, 
taken to be surrogates of  the true risk of  signiÀcant 
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hematological complications. Clinicians must also consider 
the rate of  change of  platelet counts over time, but we 
were unable to address this in our study. The PIERS 
combined adverse maternal outcome is also inadequate 
as a surrogate marker of  hematological complications. 
Although this combined outcome was rigorously deÀned 
for the development of  the PIERS models, it reÁects 
outcomes of  preeclampsia as a whole, not necessarily 
speciÀc to hematological complications. The strength of  
modelling against the PIERS combined outcome in this 
study is that this reÁects the real world clinical concerns 
associated with preeclampsia.
One strength of  this study is that the data come from a 
large, international database of  well-characterized women 
with rigorously deÀned preeclampsia. This allowed us to 
examine each sub-group of  preeclampsia. This adds to 
previous studies in which the relationship between platelet 
count and abnormal coagulation was observed only in cases 
of  severe preeclampsia, however deÀned. An additional 
strength of  our study is that, in contrast to previous 
studies, we also investigated the association between 
platelet count and adverse maternal outcome, speciÀcally 
the need for blood transfusion. Beyond identifying 
risk in order to guide clinical management, coagulation 
testing is also performed to identify women who may be 
at risk of  epidural hematoma associated with epidural 
analgesia. In previous studies using thromboelastography 
to assess the relationship between platelet count and 
abnormal coagulation, a platelet count < 100 × 109/L was 
associated with hypocoagulation in women with severe 
preeclampsia.5,29 None of  the women in these studies 
who received epidural analgesia had complications. In 
our population, neuraxial anaesthesia was used in 89.4% 
of  women with a platelet count < 100 × 109/L, and no 
complications, including epidural hematoma, were seen. 
However, we had no information about the timing of  
induction of  neuraxial anaesthesia in relation to platelet 
count or the presence of  the abnormal coagulation tests. 
Our Àndings support the opinion that regional anaesthesia 
should not be withheld from women solely because of  a 
platelet count < 100 × 109/L.11
CONCLuSION
This study conÀrms that, among women admitted to 
hospital with preeclampsia, there is a signiÀcant association 
between both a platelet count < 100 × 109/L and abnormal 
coagulation test results and an increased risk of  adverse 
maternal outcome, or blood transfusion speciÀcally. While 
a platelet count < 100 × 109/L should alert caregivers to 
the real possibility of  generalized coagulopathy, a normal 
platelet count alone should not be used as an effective 
“rule out” test for mild or moderate coagulopathy because 
of  the low sensitivity of  this test.
ACKNOWLEDGEMENTS
This study was supported by operating grants from the 
Canadian Institutes of  Health Research (CIHR) and the 
UNDP/UNFPA/WHO/World Bank Special Programme 
of  Research, Development and Research Training in 
Human Reproduction. Salary awards were received from 
the CIHR (PvD), Michael Smith Foundation for Health 
Research (LAM, PvD), and Child and Family Research 
Institute (SL, PvD).
The other members of  the PIERS (Pre-eclampsia 
Integrated Estimate of  RiSk) Study Group are Jing Li, 
Mark Ansermino, Samantha Benton, Naomi Kronitz, 
Jennifer Menzies, Alexi Millman, Keith Walley, James 
Russell (Vancouver, BC); Shoo K Lee (Toronto, Ontario); 
Jean-Marie Moutquin and Annie Ouellet (Sherbrooke, 
Québec); Graeme Smith (Kingston, Ontario); Andrée 
Gruslin (Ottawa, Ontario); James Walker (Leeds, UK); 
Fiona Broughton Pipkin and Pamela Loughna (Nottingham, 
UK), Philippa Kyle and Peter Moore (Christchurch, NZ); 
and Barry Walters (Subiaco, Western Australia).
The members of  the Delphi consensus were (from Canada) 
P von Dadelszen (maternal-fetal medicine [MFM]), 
LA Magee (obstetric internal medicine (OIM)), MJ Douglas 
(obstetric anaesthesia), KR Walley (critical care medicine 
[CCM]), JA Russell (CCM), SK Lee (neonatology), 
A Gruslin (MFM), GN Smith (MFM), AM Côté 
(OIM), J-M Moutquin (MFM); (from the United States) 
JM Roberts (MFM); (from the United Kingdom) S Robson 
(MFM), M de Swiet (OIM), and JJ Walker (MFM and 
OIM); (from Australia) MA Brown (OIM) and G Davis 
(MFM); and (from New Zealand) LA McCowan (MFM), 
P Kyle (MFM), and MP Moore (OIM).
We acknowledge the efforts of  the seven PIERS site 
co-ordinators (Lynn Bissonnette, Sherbrooke, QC; Laura 
Payant and Svetlana Shachkina, Ottawa, ON; Heather 
Ramshaw, Kingston, ON; Jane Hayes, Leeds, UK; Barbra 
Pullar, Christchurch, NZ; and Claire Parker, Subiaco, AU) 
for their assistance. Thanks to Pamela Lutley, Terry Viczko, 
Jonathan Lam, and Kelly Richardson for their tremendous 
help in getting this project underway, and to Yi Lin, Xiang 
Xuan, and Ying C MacNab for their assistance with the 
preliminary statistical analyses.
908 l SEPTEMBER JOGC SEPTEMBRE 2011
OBSTETRICS
REFERENCES
1. Hogan MC, Foreman KJ, Naghavi M, Ahn SY, Wang M, Makela SM, et al.  
Maternal mortality for 181 countries, 1980–2008: a systematic analysis 
of  progress towards Millennium Development Goal 5. Lancet 
2010;375:1609–23.
2. Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placentation, 
angiogenic factors, and the pathogenesis of  pre-eclampsia. Obstet 
Gynecol Clin North Am 2010;37:239–53.
3. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. 
Lancet 2010;376:631–44.
4. von Dadelszen P, Magee LA, Lee SK, Stewart SD, Simone C, Koren G, 
et al. Activated protein C in normal human pregnancy and pregnancies 
complicated by severe pre-eclampsia: a therapeutic opportunity?  
Crit Care Med 2002;30:1883–92.
5. Sharma SK, Philip J, Whitten CW, Padakandla UB, Landers DF. 
Assessment of  changes in coagulation in parturients with pre-eclampsia 
using thromboelastography. Anesthesiology 1999;90:385–90.
6. Kramer RL, Izquierdo LA, Gilson GJ, Curet LB, Qualls CR. 
“Preeclamptic labs” for evaluating hypertension in pregnancy.  
J Reprod Med 1997;42:223–8.
7. Leduc L, Wheeler JM, Kirshon B, Mitchell P, Cotton DB. Coagulation 
proÀle in severe pre-eclampsia. Obstet Gynecol 1992;79:14–8.
8. Magee LA, Helewa ME, Moutquin JM, von Dadelszen P, Cardew C,  
Cote AM, et al. Diagnosis, evaluation and management of  the 
hypertensive disorders of  pregnancy. SOGC Clinical Practice Guidelines, 
No. 206, March 2008. J Obstet Gynaecol Can 2008;30(3 Suppl 1):S1–S48.
9. Menzies J, Magee LA, Li J, MacNab YC, Yin R, Stuart H, et al. Instituting 
surveillance guidelines and adverse outcomes in pre-eclampsia.  
Obstet Gynecol 2007;110:121–7.
10. von Dadelszen P, Sawchuck D, McMaster R, Douglas MJ, Lee SK, 
Saunders S, et al. The active implementation of  pregnancy hypertension 
guidelines in British Columbia. Obstet Gynecol 2010;116:659–66.
11. Gogarten W. Pre-eclampsia and anaesthesia. Curr Opin Anaesth 
2009;22:347–51.
12. von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton-Pipkin F,  
Cote AM, et al. Predicting adverse maternal outcomes in  
pre-eclampsia: the fullPIERS model—development and validation.  
Lancet 2011;377:185–6.
13. Barton JR, O’Brien JM, Bergauer NK, Jacques DL, Sibai BM.  
Mild gestational hypertension remote from term: progression and 
outcome. Am J Obstet Gynecol 2001;184:979–83.
14. Homer CS, Brown MA, Mangos G, Davis GK. Non-proteinuric  
pre-eclampsia: a novel risk indicator in women with gestational 
hypertension. J Hypertens 2008;26:295–302.
15. Sibai BM, Stella CL. Diagnosis and management of  atypical  
pre-eclampsia-eclampsia. Am J Obstet Gynecol 2009;200:481.e1–481.e7.
16. Milholland AV, Wheeler SG, Heieck JJ. Medical assessment by a  
Delphi group opinion technic. N Engl J Med 1973;288:1272–5.
17. Hutchinson A, Fowler P. Outcome measures for primary health-care: 
what are the research priorities? Br J Gen Pract 1992;42:227–31.
18. Bellomo R, Kellum JA, Ronco C. DeÀning and classifying acute renal 
failure: from advocacy to consensus and validation of  the RIFLE criteria. 
Intensive Care Med 2007;33:409–13.
19. PIERS Project Resource. Full deÀnitions of  maternal adverse outcomes. 
Prediction of  adverse maternal outcomes in pre-eclampsia: development 
and validation of  the fullPIERS model. Available at:  
http://piers.cfri.ca/Resources.aspx. Accessed July 7, 2011.
20. Valera M, Parant O, Vayssiere C, Arnal J, Payrastre B. Physiologic and 
pathologic changes of  platelets in pregnancy. Platelets 2010;21:587–95.
21. Prieto JA, Mastrobattista JM, Blanco JD. Coagulation studies in patients 
with marked thrombocytopenia due to severe pre-eclampsia.  
Am J Perinatol 1995;12:220–2.
22. Barron WM, Heckerling P, Hibbard JU, Fisher S. Reducing unnecessary 
coagulation testing in hypertensive disorders of  pregnancy. Obstet 
Gynecol 1999;94:364–70.
23. Harlow FH, Brown MA, Brighton TA, Smith SL, Trickett AE, Kwan YL, 
et al. Platelet activation in the hypertensive disorders of  pregnancy.  
Am J Obstet Gynecol 2002;187:688–95.
24. Bewick V, Cheek L, Ball J. Statistics review 14: logistic regression.  
Crit Care 2005;9:112–8.
25. Anderson RP, Jin RY, Grunkemeier GL. Understanding logistic 
regression analysis in clinical reports: an introduction. Ann Thorac Surg 
2003;75:753–7.
26. von Dadelszen P, Payne B, Li J, Ansermino JM, Pipkin FB, Cote AM, et al. 
Prediction of  adverse maternal outcomes in pre-eclampsia: development 
and validation of  the fullPIERS model. Lancet 2011;377:219–27.
27. Saha SP, Bhattacharjee N, Ganguli RP, Sil S, Patra KK, Sengupta M, et al. 
Prevalence and signiÀcance of  antiphospholipid antibodies in selected  
at-risk obstetrics cases: a comparative prospective study. J Obstet 
Gynaecol 2009;29:614–8.
28. Romero R, Mazor M, Lockwood CJ, Emamian M, Belanger KP,  
Hobbins JC, et al. Clinical signiÀcance, prevalence, and natural history of  
thrombocytopenia in pregnancy-induced hypertension. Am J Perinatol 
1989;6:32–8.
29. Orlikowski CEP, Rocke DA, Murray WB, Gouws E, Moodley J,  
Kenoyer DG, et al. Thrombelastography changes in pre-eclampsia  
and eclampsia. Br J Anaesth 1996;77:157–61.
